InflaRx (IFRX) EBT (2016 - 2026)
InflaRx (IFRX) posted EBT of -$8.0 million for Q1 2026, down 119.29% sequentially from $41.6 million in Q4 2025, and up 38.97% YoY from -$5.8 million in Q1 2025.
InflaRx (IFRX) EBT (2016 - 2026) Analysis & Trends
InflaRx has reported EBT for 11 years, with the latest figure at -$8.0 million in Q1 2026.
- Quarterly EBT rose 38.97% year-over-year to -$8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 million (up 341.99% YoY) and the FY2025 annual result came in at -$51.9 million, down 4.03% from the prior year.
- EBT retreated to -$8.0 million in Q1 2026 per IFRX's latest filing, from $41.6 million in the prior quarter.
- Over five years, EBT peaked at $46.9 million in Q4 2024 and troughed at -$16.0 million in Q3 2024.
- A 5-year average of -$4.3 million and a median of -$11.9 million in 2023 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2024: EBT slumped 350.62% in 2022, then surged 455.3% in 2024.
- Over 5 years, EBT stood at -$14.1 million in 2022, then rose by 6.63% to -$13.2 million in 2023, then surged by 455.3% to $46.9 million in 2024, then dropped by 11.21% to $41.6 million in 2025, then sank by 119.29% to -$8.0 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$8.0 million, $41.6 million, and -$10.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | InflaRx | 135.25 Mn | -49.00 Mn | 2.74 Bn | -7.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.03 Mn |
| Dec 31, 2025 | 41.63 Mn |
| Sep 30, 2025 | -10.55 Mn |
| Jun 30, 2025 | -14.04 Mn |
| Mar 31, 2025 | -13.16 Mn |
| Dec 31, 2024 | 46.89 Mn |
| Sep 30, 2024 | -16.02 Mn |
| Jun 30, 2024 | -15.68 Mn |
| Mar 31, 2024 | -12.58 Mn |
| Dec 31, 2023 | -13.20 Mn |
| Sep 30, 2023 | -10.84 Mn |
| Jun 30, 2023 | -9.55 Mn |
| Mar 31, 2023 | -11.91 Mn |
| Dec 31, 2022 | -14.14 Mn |
| Sep 30, 2022 | -3.63 Mn |
| Jun 30, 2022 | 5.20 Mn |
| Mar 31, 2022 | -14.24 Mn |
| Dec 31, 2021 | -44,446.67 Bn |
| Sep 30, 2021 | -11.23 Mn |
| Jun 30, 2021 | -19.52 Mn |